Chemed price target raised to $650 from $625 at Oppenheimer

Oppenheimer raised the firm’s price target on Chemed to $650 from $625 and keeps an Outperform rating on the shares. The firm notes Chemed reported strong Q4 results and issued solid 2024 guidance. Vitas continued to perform well, with continued growth in hiring, admissions, and LOS that drove ADC above pre-pandemic levels.